KLH-2109 + Leuprorelin
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Fibroids (MeSH Heading: Leiomyoma)
Conditions
Uterine Fibroids (MeSH Heading: Leiomyoma)
Trial Timeline
Oct 11, 2022 → Aug 21, 2024
NCT ID
NCT05440383About KLH-2109 + Leuprorelin
KLH-2109 + Leuprorelin is a phase 3 stage product being developed by Kissei Pharmaceutical for Uterine Fibroids (MeSH Heading: Leiomyoma). The current trial status is completed. This product is registered under clinical trial identifier NCT05440383. Target conditions include Uterine Fibroids (MeSH Heading: Leiomyoma).
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05440383 | Phase 3 | Completed |
Competing Products
20 competing products in Uterine Fibroids (MeSH Heading: Leiomyoma)